BBR Partners LLC Buys 708 Shares of Novartis AG (NYSE:NVS)

BBR Partners LLC grew its stake in Novartis AG (NYSE:NVSGet Rating) by 27.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,273 shares of the company’s stock after acquiring an additional 708 shares during the quarter. BBR Partners LLC’s holdings in Novartis were worth $286,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in NVS. Renaissance Technologies LLC grew its position in shares of Novartis by 37.2% in the 3rd quarter. Renaissance Technologies LLC now owns 3,307,237 shares of the company’s stock valued at $270,466,000 after purchasing an additional 897,298 shares during the period. Wellington Management Group LLP grew its position in shares of Novartis by 21.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,214,932 shares of the company’s stock valued at $344,696,000 after purchasing an additional 745,157 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Novartis by 3,631.4% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 723,900 shares of the company’s stock valued at $59,201,000 after purchasing an additional 704,500 shares during the period. Principal Financial Group Inc. grew its position in shares of Novartis by 24.1% in the 3rd quarter. Principal Financial Group Inc. now owns 2,068,564 shares of the company’s stock valued at $169,168,000 after purchasing an additional 401,585 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Novartis by 101.2% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 677,369 shares of the company’s stock valued at $55,395,000 after purchasing an additional 340,669 shares during the period. 9.72% of the stock is owned by institutional investors.

Shares of NYSE NVS traded up $0.10 during trading hours on Thursday, hitting $89.51. The company had a trading volume of 28,158 shares, compared to its average volume of 2,636,617. The stock has a market capitalization of $200.21 billion, a P/E ratio of 8.40, a price-to-earnings-growth ratio of 2.57 and a beta of 0.55. The company has a quick ratio of 1.29, a current ratio of 1.51 and a debt-to-equity ratio of 0.34. Novartis AG has a 1-year low of $79.09 and a 1-year high of $95.17. The firm’s 50 day moving average is $87.66 and its 200-day moving average is $85.74.

Novartis (NYSE:NVSGet Rating) last released its quarterly earnings data on Monday, April 25th. The company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.45 by $0.01. The company had revenue of $12.53 billion during the quarter, compared to the consensus estimate of $12.61 billion. Novartis had a return on equity of 24.57% and a net margin of 46.27%. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.52 EPS. On average, sell-side analysts predict that Novartis AG will post 6.19 earnings per share for the current year.

The firm also recently declared an annual dividend, which was paid on Thursday, March 17th. Investors of record on Wednesday, March 9th were paid a $1.175 dividend. This represents a yield of 1.36%. The ex-dividend date of this dividend was Tuesday, March 8th. Novartis’s dividend payout ratio (DPR) is presently 20.28%.

Several equities analysts recently issued reports on NVS shares. Societe Generale decreased their price objective on Novartis from CHF 107 to CHF 105 in a research report on Thursday, February 3rd. Stifel Nicolaus began coverage on Novartis in a research report on Monday, February 28th. They set a “hold” rating for the company. Barclays upped their price target on Novartis from CHF 80 to CHF 85 in a research report on Thursday, April 14th. UBS Group upped their price target on Novartis from CHF 85 to CHF 88 and gave the stock a “neutral” rating in a research report on Wednesday. Finally, raised Novartis from a “hold” rating to a “buy” rating in a research report on Thursday, April 14th. Three analysts have rated the stock with a sell rating, six have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $90.00.

About Novartis (Get Rating)

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.

Featured Stories

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVSGet Rating).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.